118 Results

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. Drilon
    Drilon
  4. Morris
    Morris
  5. Scher
    Scher
  6. Ladanyi
    Ladanyi
  7. Voss
    Voss
  8. Carlo
    Carlo
  9. Feldman
    Feldman
  10. Kotecha
    Kotecha

Groups

  1. Department of Medicine (105)
  2. Solid Tumor Oncology Division (97)
  3. Genitourinary Oncology Service (55)
  4. Thoracic Oncology (19)
  5. Gastrointestinal Oncology Service (18)
  6. GSK Faculty (14)
  7. Sloan Kettering Institute Postdocs (14)
  8. Radiology, Department of (13)
  9. Weinberg Fellows (12)
  10. Department of Pathology and Laboratory Medicine (11)
  1. "cabozantinib"
Formats
  1. Journal Article (88)
  2. Review (18)
  3. Editorial (4)
  4. Research Letter (3)
  5. Correspondence (2)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (105)
  2. Solid Tumor Oncology Division (97)
  3. Genitourinary Oncology Service (55)
  4. Thoracic Oncology (19)
  5. Gastrointestinal Oncology Service (18)
  6. GSK Faculty (14)

More Groups

People
  1. Robert Motzer (25)
  2. Alexander Drilon (16)
  3. Ghassan Abou-Alfa (16)
  4. Michael Morris (11)
  5. Howard Scher (8)
  6. Marc Ladanyi (7)

More People

Years
  1. 2025 (8)
  2. 2024 (11)
  3. 2023 (12)
  4. 2022 (15)
  5. 2021 (7)
  6. 2020 (18)

More Years

Publications
  1. European Urology (8)
  2. Clinical Cancer Research (6)
  3. European Journal of Cancer (6)
  4. New England Journal of Medicine (6)
  5. Journal of Thoracic Oncology (5)
  6. Current Treatment Options in Oncology (4)

More Publications

Publishers
  1. Elsevier Inc. (23)
  2. Elsevier Science, Inc. (14)
  3. American Association for Cancer Research (8)
  4. Oxford University Press (7)
  5. Massachusetts Medical Society (6)
  6. Springer (5)

More Publishers

Results (118)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
    Journal Article

    Freemantle, N.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Mangeshkar, M.; Abou-Alfa, G. K.
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial
    Journal Article

    Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial
    Journal Article

    El-Khoueiry, A. B.; Meyer, T.; Cheng, A. L.; Rimassa, L.; Sen, S.; Milwee, S.; Kelley, R. K.; Abou-Alfa, G. K.
    BMC Cancer (2022)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Journal Article

    Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; Chan, Y. W.; more...
    Liver Cancer (2022)

    Fulltext@MSK | Save
  • Evaluating treatment tolerability using the toxicity index with patient-reported outcomes data
    Journal Article

    Langlais, B.; Mazza, G. L.; Thanarajasingam, G.; Rogak, L. J.; Ginos, B.; Heon, N.; Scher, H. I.; Schwab, G.; Ganz, P. A.; Basch, E.; more...
    Journal of Pain and Symptom Management (2022)

    Fulltext@MSK | Save
  • Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: A sub-analysis of the METEOR study
    Journal Article

    Schmidinger, M.; Motzer, R. J.; Rolland, F.; Staehler, M.; Rink, M.; Retz, M.; Csoszi, T.; McCaffrey, J. A.; De Giorgi, U.; Caserta, C.; more...
    Acta Oncologica (2022)

    Fulltext@MSK | Save
  • In silico modeling of combination systemic therapy for advanced renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Hsu, D. J.; Lee, C. H.; Patil, S.; Voss, M. H.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of germline testing in patients with advanced cancers
    Journal Article

    Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
    Review

    Rinke, A.; Auernhammer, C. J.; Bodei, L.; Kidd, M.; Krug, S.; Lawlor, R.; Marinoni, I.; Perren, A.; Scarpa, A.; Sorbye, H.; more...
    Gut (2021)

    Fulltext@MSK | Save
  • Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
    Journal Article

    Powles, T.; Choueiri, T. K.; Motzer, R. J.; Jonasch, E.; Pal, S.; Tannir, N. M.; Signoretti, S.; Kaldate, R.; Scheffold, C.; Wang, E.; more...
    BMC Cancer (2021)

    Fulltext@MSK | Save